The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06637631




Registration number
Help: Registration number
NCT06637631
Ethics application status
Help: Ethics application status
Date submitted
Help: Date submitted
10/10/2024
Date registered
Help: Date registered
15/10/2024
Date last updated
Help: Date last updated
13/10/2026

Titles & IDs
Public title
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
Scientific title
A Phase 2, Multinational, Multicenter, Randomized, Doubleblind, Placebocontrolled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Crohn's Disease.
Additional trial identifiers [1] 0 0
2024-512633-32-00
Additional trial identifiers [2] 0 0
DRI18212
Universal Trial Number (UTN)
Trial acronym
SPECIFI-CD
Related trial records

Health condition
Health condition(s) studied:
Crohn's Disease 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Inflammatory bowel disease
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Oral and Gastrointestinal 0 0 0 0
Crohn's disease

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Treatment: Drugs - SAR441566
Treatment: Drugs - SAR441566 matching Placebo

Experimental: SAR441566 dose 1 - Participants will receive SAR441566 dose 1.

Experimental: SAR441566 dose 2 - Participants will receive SAR441566 dose 2.

Experimental: SAR441566 dose 3 - Participants will receive SAR441566 dose 3.

Placebo comparator: Placebo - Participants will receive SAR441566 matching placebo.


Treatment: Drugs: SAR441566
Pharmaceutical form: Tablet Route of administration: Oral

Treatment: Drugs: SAR441566 matching Placebo
Pharmaceutical form: Tablet Route of administration: Oral

Intervention code [1] 0 0
Treatment: Drugs
Description of the comparator or control
Control group

Outcomes
Primary outcome [1] 0 0
Proportion of participants achieving endoscopic response
Timepoint [1] 0 0
Week 12
Secondary outcome [1] 0 0
Proportion of participants achieving clinical remission based on Crohn's Disease Activity Index (CDAI)
Timepoint [1] 0 0
Week 12
Secondary outcome [2] 0 0
Proportion of participants achieving Patient-Reported Outcome (PRO-2) remission
Timepoint [2] 0 0
Week 12
Secondary outcome [3] 0 0
Proportion of participants achieving both clinical remission and endoscopic response
Timepoint [3] 0 0
Week 12
Secondary outcome [4] 0 0
Proportion of participants achieving endoscopic remission based on centrally read SES-CD
Timepoint [4] 0 0
From Baseline to Week 12
Secondary outcome [5] 0 0
Proportion of participants achieving CDAI clinical response
Timepoint [5] 0 0
From Baseline to Week 12
Secondary outcome [6] 0 0
Proportion of participants achieving Inflammatory Bowel Disease Questionnaire (IBDQ) remission
Timepoint [6] 0 0
Week 12
Secondary outcome [7] 0 0
Proportion of participants achieving IBDQ response
Timepoint [7] 0 0
From baseline to Week 12
Secondary outcome [8] 0 0
Change from baseline in the IBDQ scores
Timepoint [8] 0 0
From Baseline to week 12
Secondary outcome [9] 0 0
Plasma pre-dose concentrations of SAR441566 at selected visits
Timepoint [9] 0 0
Up to week 52
Secondary outcome [10] 0 0
Plasma post-dose concentrations of SAR441566 at selected visits
Timepoint [10] 0 0
Up to week 52
Secondary outcome [11] 0 0
Number of participants experiencing any TEAEs
Timepoint [11] 0 0
Up to week 52
Secondary outcome [12] 0 0
Number of participants experiencing any TEAEs
Timepoint [12] 0 0
From week 12 to week 52

Eligibility
Key inclusion criteria
Participants are eligible to be included in the study only if all of the following criteria apply:

1. Male or female participants aged 18 to 75 years at the time of signing the ICF
2. Confirmed diagnosis of CD for at least 3 months prior to Baseline
3. Confirmed diagnosis of moderate to severe CD as assessed by:

* Crohn's Disease Activity Index (CDAI) score and the Simple Endoscopic Score for Crohn's disease (SES-CD) on an endoscopy confirmed by a central reader
* stool frequency (SF), abdominal pain (AP) score
4. History of prior exposure to standard treatment (5-ASA, steroids, immunomodulators or antibiotics) or advanced therapies (biologics or small molecules), but having inadequate response to, loss or response to or intolerance to at least one of these therapies
5. On stable doses of standard treatments prior to screening (oral 5-ASA compounds, oral corticosteroids, thiopurines (eg. AZA, 6-MP), or MTX)
6. Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Women participants should not be pregnant or breastfeeding.
Minimum age
18 Years
Maximum age
75 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Participants are excluded from the study if any of the following criteria apply:

1. Participants with active UC, indeterminate colitis or short bowel syndrome
2. Participants with CD isolated to the stomach, duodenum, jejunum, or peri anal region, without colonic or ileal involvement
3. Participants with following ongoing known complications of CD: fistula, abscess, symptomatic stricture/stenosis, fulminant colitis, toxic megacolon, recent bowel resection within 3 months of screening or history of > 3 bowel resections
4. Participants with stool sample positive for infectious pathogens
5. Participants with active tuberculosis (TB) or a history of incompletely treated active or latent TB per local guidelines
6. Participants with Positive Hepatitis B surface antigen (HBsAg) or positive Hepatitis B core antibody (HBcAb); and/or positive Hepatitis C antibody (HCV) at the Screening Visit
7. Participants with any other active, chronic or recurrent infection, including recurrent or disseminated herpes zoster or disseminated herpes simplex
8. Participants with a known history of Human Immunodeficiency Virus (HIV) infection or positive HIV-1 or HIV-2 serology at screening
9. Participants presenting with active malignancies, lymphoproliferative disease, or recurrence of either, within the 5 years before screening
10. History of colonic mucosal dysplasia or presence of colonic mucosal dysplasia or adenomatous colonic polyps not removed during colonoscopy at screening visit
11. Infection(s) requiring treatment with IV anti infectives within 30 days or oral/intramuscular anti-infectives within 14 days prior to the screening visit
12. Participants requiring or receiving any parental nutrition and/or exclusive enteral nutrition
13. Participants who received cyclosporine, tacrolimus, mycophenolate mofetil, or thalidomide within 30 days prior to screening
14. Participants who received fecal microbial transplantation within 30 days prior to screening
15. Participants who have ever been exposed to natalizumab (Tysabri®) or oral carotegrast methyl (Carogra®)
16. Participants who received IV corticosteroids within 14 days prior to screening or during screening period
17. Participants who received therapeutic enema or suppository, other than required for colonoscopy within 14 days prior to screening or during screening
18. Screening laboratory and other analyses show abnormal results

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Investigational Site Number : 0360002 - Sydney
Recruitment hospital [2] 0 0
Investigational Site Number : 0360001 - South Brisbane
Recruitment hospital [3] 0 0
Investigational Site Number : 0360003 - Parkville
Recruitment postcode(s) [1] 0 0
2139 - Sydney
Recruitment postcode(s) [2] 0 0
4101 - South Brisbane
Recruitment postcode(s) [3] 0 0
3050 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Connecticut
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Illinois
Country [5] 0 0
United States of America
State/province [5] 0 0
Michigan
Country [6] 0 0
United States of America
State/province [6] 0 0
Mississippi
Country [7] 0 0
United States of America
State/province [7] 0 0
Nevada
Country [8] 0 0
United States of America
State/province [8] 0 0
New York
Country [9] 0 0
United States of America
State/province [9] 0 0
North Carolina
Country [10] 0 0
United States of America
State/province [10] 0 0
Pennsylvania
Country [11] 0 0
United States of America
State/province [11] 0 0
South Carolina
Country [12] 0 0
United States of America
State/province [12] 0 0
Texas
Country [13] 0 0
United States of America
State/province [13] 0 0
Washington
Country [14] 0 0
Argentina
State/province [14] 0 0
Tucumán Province
Country [15] 0 0
Argentina
State/province [15] 0 0
Buenos Aires
Country [16] 0 0
Brazil
State/province [16] 0 0
Estado de Bahia
Country [17] 0 0
Brazil
State/province [17] 0 0
Rio Grande do Sul
Country [18] 0 0
Brazil
State/province [18] 0 0
São Paulo
Country [19] 0 0
Bulgaria
State/province [19] 0 0
Gorna Oryahovitsa
Country [20] 0 0
Bulgaria
State/province [20] 0 0
Sofia
Country [21] 0 0
Canada
State/province [21] 0 0
Alberta
Country [22] 0 0
Canada
State/province [22] 0 0
Quebec
Country [23] 0 0
Chile
State/province [23] 0 0
Biobio
Country [24] 0 0
Chile
State/province [24] 0 0
Reg Metropolitana de Santiago
Country [25] 0 0
Chile
State/province [25] 0 0
Valparaiso
Country [26] 0 0
China
State/province [26] 0 0
Changzhou
Country [27] 0 0
China
State/province [27] 0 0
Chongqing
Country [28] 0 0
China
State/province [28] 0 0
Fuzhou
Country [29] 0 0
China
State/province [29] 0 0
Guangzhou
Country [30] 0 0
China
State/province [30] 0 0
Hangzhou
Country [31] 0 0
China
State/province [31] 0 0
Hefei
Country [32] 0 0
China
State/province [32] 0 0
Nanchang
Country [33] 0 0
China
State/province [33] 0 0
Shanghai
Country [34] 0 0
China
State/province [34] 0 0
Suzhou
Country [35] 0 0
Croatia
State/province [35] 0 0
Osijek
Country [36] 0 0
Croatia
State/province [36] 0 0
Zagreb
Country [37] 0 0
Czechia
State/province [37] 0 0
Brno
Country [38] 0 0
Czechia
State/province [38] 0 0
Olomouc
Country [39] 0 0
Czechia
State/province [39] 0 0
Prague
Country [40] 0 0
France
State/province [40] 0 0
Montpellier
Country [41] 0 0
France
State/province [41] 0 0
Nice
Country [42] 0 0
France
State/province [42] 0 0
Saint-Priest-en-Jarez
Country [43] 0 0
France
State/province [43] 0 0
Toulouse
Country [44] 0 0
France
State/province [44] 0 0
Vandœuvre-lès-Nancy
Country [45] 0 0
Georgia
State/province [45] 0 0
Kutaisi
Country [46] 0 0
Georgia
State/province [46] 0 0
Tbilisi
Country [47] 0 0
Germany
State/province [47] 0 0
Berlin
Country [48] 0 0
Germany
State/province [48] 0 0
Fulda
Country [49] 0 0
Germany
State/province [49] 0 0
Halle
Country [50] 0 0
Germany
State/province [50] 0 0
Ludwigshafen
Country [51] 0 0
Germany
State/province [51] 0 0
Magdeburg
Country [52] 0 0
Germany
State/province [52] 0 0
Nordhausen
Country [53] 0 0
Hungary
State/province [53] 0 0
Békéscsaba
Country [54] 0 0
Hungary
State/province [54] 0 0
Budapest
Country [55] 0 0
Hungary
State/province [55] 0 0
Eger
Country [56] 0 0
Hungary
State/province [56] 0 0
Gyöngyös
Country [57] 0 0
Hungary
State/province [57] 0 0
Szeged
Country [58] 0 0
Hungary
State/province [58] 0 0
Szekszárd
Country [59] 0 0
Hungary
State/province [59] 0 0
Tatabánya
Country [60] 0 0
India
State/province [60] 0 0
Hyderabad
Country [61] 0 0
India
State/province [61] 0 0
Jaipur
Country [62] 0 0
India
State/province [62] 0 0
Kolkata
Country [63] 0 0
India
State/province [63] 0 0
Pune
Country [64] 0 0
India
State/province [64] 0 0
Secunderabad
Country [65] 0 0
India
State/province [65] 0 0
Surat
Country [66] 0 0
Italy
State/province [66] 0 0
Milano
Country [67] 0 0
Italy
State/province [67] 0 0
Padova
Country [68] 0 0
Italy
State/province [68] 0 0
Roma
Country [69] 0 0
Italy
State/province [69] 0 0
Pisa
Country [70] 0 0
Japan
State/province [70] 0 0
Chiba
Country [71] 0 0
Japan
State/province [71] 0 0
Fukuoka
Country [72] 0 0
Japan
State/province [72] 0 0
Hokkaido
Country [73] 0 0
Japan
State/province [73] 0 0
Iwate
Country [74] 0 0
Japan
State/province [74] 0 0
Kagawa-ken
Country [75] 0 0
Japan
State/province [75] 0 0
Niigata
Country [76] 0 0
Japan
State/province [76] 0 0
Tokyo
Country [77] 0 0
Japan
State/province [77] 0 0
Hiroshima
Country [78] 0 0
Japan
State/province [78] 0 0
Oita
Country [79] 0 0
Japan
State/province [79] 0 0
Wakayama
Country [80] 0 0
Mauritius
State/province [80] 0 0
Vacoas
Country [81] 0 0
Netherlands
State/province [81] 0 0
Breda
Country [82] 0 0
Netherlands
State/province [82] 0 0
Nijmegen
Country [83] 0 0
Netherlands
State/province [83] 0 0
Tilburg
Country [84] 0 0
Netherlands
State/province [84] 0 0
Utrecht
Country [85] 0 0
Poland
State/province [85] 0 0
Kuyavian-Pomeranian Voivodeship
Country [86] 0 0
Poland
State/province [86] 0 0
Lublin Voivodeship
Country [87] 0 0
Poland
State/province [87] 0 0
Masovian Voivodeship
Country [88] 0 0
Poland
State/province [88] 0 0
Pomeranian Voivodeship
Country [89] 0 0
Romania
State/province [89] 0 0
Bucharest
Country [90] 0 0
Romania
State/province [90] 0 0
Cluj-Napoca
Country [91] 0 0
Romania
State/province [91] 0 0
Constan?a
Country [92] 0 0
Romania
State/province [92] 0 0
Timi?oara
Country [93] 0 0
South Korea
State/province [93] 0 0
Busan
Country [94] 0 0
South Korea
State/province [94] 0 0
Daegu
Country [95] 0 0
South Korea
State/province [95] 0 0
Daejeon
Country [96] 0 0
South Korea
State/province [96] 0 0
Gangwon-do
Country [97] 0 0
Spain
State/province [97] 0 0
Madrid, Comunidad de
Country [98] 0 0
Spain
State/province [98] 0 0
Sevilla
Country [99] 0 0
Turkey (Türkiye)
State/province [99] 0 0
Mersin
Country [100] 0 0
Turkey (Türkiye)
State/province [100] 0 0
Sanliurfa

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Sanofi
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Trial Transparency email recommended (Toll free for US & Canada)
Address 0 0
Country 0 0
Phone 0 0
800-633-1610
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
When will data be available (start and end dates)?
Available to whom?
Available for what types of analyses?
How or where can data be obtained?


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

No documents have been uploaded by study researchers.